Nuvation Bio Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Nuvation Bio Inc.
- Former names
- Panacea Acquisition Corp
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- New York
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- NUVB
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001811063
- EIN
- 85-0862255
Board of directors
-
Daniel G. Welch · DirectorSince 2023
-
David Hung · Director · PRESIDENT AND CEOSince 2023
-
Junyuan Jerry Wang · Director · CEO, ANHEART THERAPEUTICS LTD.Since 2024
-
Kathryn E. Falberg · DirectorSince 2023
-
Kim D. Blickenstaff · DirectorSince 2023
-
Oleg Nodelman · DirectorSince 2023
-
Robert B. Bazemore · DirectorSince 2023
-
Robert Mashal · DirectorSince 2024
-
W. Anthony Vernon · DirectorSince 2023
-
Xiangmin Cui · DirectorSince 2024
Chief executives
Junyuan Jerry Wang
· CEO, ANHEART THERAPEUTICS LTD.
Since April 2024
David Hung
· PRESIDENT AND CEO
Until April 2024
· Former
Director election results
Annual meeting of May 21, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.0%
-
92.1%
-
100.0%
Board connections
7 of this board's directors also sit on 13 other boards.
- via David Hung and W. Anthony Vernon
- via Robert B. Bazemore
- via Oleg Nodelman
- via Oleg Nodelman
- via Kathryn E. Falberg
- via Robert B. Bazemore
- via W. Anthony Vernon
- via Daniel G. Welch
- via Daniel G. Welch
- via Kim D. Blickenstaff
- via Kathryn E. Falberg
- via Daniel G. Welch
- via Oleg Nodelman
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $118,250
- 1 purchase by 1 insider
- Sold, last 12 months
- $9,682,141
- 17 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 19, 2026 | Hattersley Gary Officer (CHIEF SCIENTIFIC OFFICER) | Option exercise | +100,000 | $1.87 | $187,000 |
| Aug 19, 2026 | Hattersley Gary Officer (CHIEF SCIENTIFIC OFFICER) | Open-market sale | −100,000 | $7.09 | $709,240 |
| Jul 15, 2026 | Sauvage Philippe Officer (Chief Financial Officer) | Option exercise | +39,999 | $2.17 | $86,798 |
| Jul 15, 2026 | Sauvage Philippe Officer (Chief Financial Officer) | Option exercise | +1 | $1.97 | $2 |
| Jun 23, 2026 | Markel Stacy Officer (CHIEF PEOPLE OFFICER) | Option exercise | +90,380 | $1.87 | $169,011 |
| Jun 23, 2026 | Wentworth Kerry Officer (CHIEF REGULATORY OFFICER) | Option exercise | +63,000 | $2.93 | $184,590 |
| Jun 23, 2026 | Sauvage Philippe Officer (Chief Financial Officer) | Option exercise | +47,668 | $2.17 | $103,440 |
| Jun 23, 2026 | Markel Stacy Officer (CHIEF PEOPLE OFFICER) | Option exercise | +34,620 | $1.74 | $60,239 |
| Jun 23, 2026 | Wentworth Kerry Officer (CHIEF REGULATORY OFFICER) | Open-market sale | −63,000 | $6.02 | $379,260 |
| Jun 23, 2026 | Sauvage Philippe Officer (Chief Financial Officer) | Open-market sale | −47,668 | $6.01 | $286,485 |
| Jun 23, 2026 | Markel Stacy Officer (CHIEF PEOPLE OFFICER) | Open-market sale | −125,000 | $6.03 | $753,750 |
| Jun 9, 2026 | Robert Mashal Director | Open-market purchase | +25,000 | $4.73 | $118,250 |
| Apr 17, 2026 | Wentworth Kerry Officer (CHIEF REGULATORY OFFICER) | Option exercise | +36,750 | $2.93 | $107,678 |
| Apr 17, 2026 | Liu Dongfang Officer (CHIEF MEDICAL OFFICER) | Option exercise | +50,000 | $1.94 | $97,000 |
| Apr 17, 2026 | Wentworth Kerry Officer (CHIEF REGULATORY OFFICER) | Open-market sale | −36,750 | $5.01 | $184,118 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.